

Acute Leukemia

CHI Formulary Treatment algorithm

Treatment algorithm- August 2023

Supporting treatment algorithms for the clinical management of Acute Leukemia

Figures 1 to 4 outline a comprehensive treatment algorithm on the Acute promyelocytic leukemia, acute myeloid leukemia, B-cell acute lymphoblastic leukemia and T-cell acute lymphoblastic leukemia respectively, aimed at addressing the different lines of treatment after thorough review of medical and economic evidence by CHI committees.

For further evidence, please refer to CHI **Acute Leukemia** full report. You can stay updated on the upcoming changes to our formulary by visiting our website at https://chi.gov.sa/AboutCCHI/CCHIprograms/Pages/IDF.aspx

Our treatment algorithm offers a robust framework for enhancing patient care and optimizing treatment outcomes across a range of treatment options, holding great promise for improving healthcare delivery.




Figure 1: Treatment algorithms for Acute promyelocytic leukemia¹

1 ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up (2022)





Figure 2: Treatment algorithm for acute myeloid leukemia



² ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up (2022)





Figure 3:Treatment algorithm for B-cell acute lymphoblastic leukemia



3

 $^{{\}mbox{\footnote{1}}}$ NCCN Acute Lymphoblastic Leukemia Guidelines for Version 1.2023




Figure 4:Treatment algorithm for T-cell acute lymphoblastic leukemia

⁴ NCCN Acute Lymphoblastic Leukemia Guidelines for Version 1.2023